Literature DB >> 24678005

Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation.

Aldo J Montano-Loza1, Judith Meza-Junco, Vickie E Baracos, Carla M M Prado, Mang Ma, Glenda Meeberg, Crystal Beaumont, Puneeta Tandon, Nina Esfandiari, Michael B Sawyer, Norman Kneteman.   

Abstract

Muscle depletion or sarcopenia is associated with increased mortality in patients with cirrhosis; how it affects mortality after liver transplantation requires further study. In this study, we aimed to establish whether sarcopenia predicts increased morbidity or mortality after liver transplantation. We analyzed 248 patients with cirrhosis who had a computed tomography (CT) scan including the third lumbar vertebra before liver transplantation. Data were recovered from medical charts, the skeletal muscle cross-sectional area was measured with CT, and sarcopenia was defined with previously published sex- and body mass index-specific cutoffs. One hundred sixty-nine patients (68%) were male, and the mean age at transplantation was 55 ± 1 years. The etiologies of cirrhosis were hepatitis C virus (51%), alcohol (19%), autoimmune liver diseases (15%), hepatitis B virus (8%), and other etiologies (7%). Sarcopenia was present in 112 patients (45%), and it was more frequent in males (P = 0.002), patients with ascites (P = 0.02), and patients with higher bilirubin levels (P = 0.05), creatinine levels (P = 0.02), international normalized ratios (P = 0.04), Child-Pugh scores (P = 0.002), and Model for End-Stage Liver Disease scores (P = 0.002). The median survival period after liver transplantation was 117 ± 17 months for sarcopenic patients and 146 ± 20 months for nonsarcopenic patients (P = 0.4). Sarcopenic patients had longer hospital stays (40 ± 4 versus 25 ± 3 days; P = 0.005) and a higher frequency of bacterial infections within the first 90 days after liver transplantation (26% versus 15%, P = 0.04) in comparison with nonsarcopenic patients. In conclusion, sarcopenia is one of the most common complications in patients with cirrhosis and is predictive of longer hospital stays and a higher risk of perioperative bacterial infections after liver transplantation, but it is not associated with increased mortality.
© 2014 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2014        PMID: 24678005     DOI: 10.1002/lt.23863

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  72 in total

1.  A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation.

Authors:  Elizabeth J Carey; Jennifer C Lai; Christopher Sonnenday; Elliot B Tapper; Puneeta Tandon; Andres Duarte-Rojo; Michael A Dunn; Cynthia Tsien; Eric R Kallwitz; Vicky Ng; Srinivasan Dasarathy; Matthew Kappus; Mustafa R Bashir; Aldo J Montano-Loza
Journal:  Hepatology       Date:  2019-08-19       Impact factor: 17.425

2.  Impact of muscle wasting on survival in patients with liver cirrhosis.

Authors:  Maria Kalafateli; Christos Konstantakis; Konstantinos Thomopoulos; Christos Triantos
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

3.  Sarcopenia in liver transplant recipients: its relevance to peritransplant morbidity and mortality.

Authors:  Hideaki Uchiyama
Journal:  Hepatobiliary Surg Nutr       Date:  2017-06       Impact factor: 7.293

4.  Automated body composition analysis of clinically acquired computed tomography scans using neural networks.

Authors:  Michael T Paris; Puneeta Tandon; Daren K Heyland; Helena Furberg; Tahira Premji; Gavin Low; Marina Mourtzakis
Journal:  Clin Nutr       Date:  2020-01-22       Impact factor: 7.324

5.  Measuring Abdominal Circumference and Skeletal Muscle From a Single Cross-Sectional Computed Tomography Image: A Step-by-Step Guide for Clinicians Using National Institutes of Health ImageJ.

Authors:  Sandra L Gomez-Perez; Jacob M Haus; Patricia Sheean; Bimal Patel; Winnie Mar; Vivek Chaudhry; Liam McKeever; Carol Braunschweig
Journal:  JPEN J Parenter Enteral Nutr       Date:  2015-09-21       Impact factor: 4.016

6.  A multicenter study to define sarcopenia in patients with end-stage liver disease.

Authors:  Elizabeth J Carey; Jennifer C Lai; Connie W Wang; Srinivasan Dasarathy; Iryna Lobach; Aldo J Montano-Loza; Michael A Dunn
Journal:  Liver Transpl       Date:  2017-05       Impact factor: 5.799

7.  A Pilot Study of Racial Differences in the Current Definition of Sarcopenia among Liver Transplant Candidates.

Authors:  Tomoki Sempokuya; Leigh Yokoyama-Arakaki; Linda L Wong; Sumodh Kalathil
Journal:  Hawaii J Health Soc Welf       Date:  2020-05-01

8.  Frailty as Tested by Gait Speed is an Independent Risk Factor for Cirrhosis Complications that Require Hospitalization.

Authors:  Michael A Dunn; Deborah A Josbeno; Amit D Tevar; Vikrant Rachakonda; Swaytha R Ganesh; Amy R Schmotzer; Elizabeth A Kallenborn; Jaideep Behari; Douglas P Landsittel; Andrea F DiMartini; Anthony Delitto
Journal:  Am J Gastroenterol       Date:  2016-08-30       Impact factor: 10.864

Review 9.  Role of Nutrition and Muscle in Cirrhosis.

Authors:  Ragesh B Thandassery; Aldo J Montano-Loza
Journal:  Curr Treat Options Gastroenterol       Date:  2016-06

Review 10.  Should Sarcopenia Increase Priority for Transplant or Is It a Contraindication?

Authors:  Guido Stirnimann; Maryam Ebadi; Puneeta Tandon; Aldo J Montano-Loza
Journal:  Curr Gastroenterol Rep       Date:  2018-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.